Jeevan Scientific Technology
64.00
+0.70(+1.11%)
Market Cap₹127.49 Cr
PE Ratio-60.87
IndustryHealthcare
Company Performance:
1D+1.11%
1M-3.54%
6M+82.86%
1Y+52.71%
5Y+2.40%
View Company Insightsright
More news about Jeevan Scientific Technology
12Nov 25
Jeevan Scientific Technology Reports Net Loss in Q2 Amid Revenue Decline
Jeevan Scientific Technology Limited reported a consolidated net loss before tax of ₹369.90 lakhs for the half year ended September 30, compared to a profit of ₹5.07 lakhs in the previous fiscal year. Standalone net loss before tax was ₹268.56 lakhs. Despite losses, cash and cash equivalents increased to ₹77.42 lakhs from ₹20.59 lakhs. Total assets rose to ₹8,380.67 lakhs, while current liabilities significantly increased to ₹7,345.27 lakhs. The company's subsidiary, Nayas Laboratories, contributed positively with a net profit after tax of ₹9.50 lakhs for the quarter.
 no imag found
08Nov 25
Jeevan Scientific Technology Completes US FDA Remote Evaluation Successfully
Jeevan Scientific Technology Limited successfully completed a Remote Interactive Evaluation (RIE) by the US FDA for its Clinical Pharmacology facility. The evaluation, conducted from October 17 to November 6, 2025, covered BA/BE studies, operations, systems, and procedures, concluding with no critical observations. This outcome demonstrates the company's adherence to regulatory standards and may enhance its credibility in the pharmaceutical research sector.
 no imag found
15Oct 25
Jeevan Scientific Technology Unveils Rs. 30.74 Crore Capital Raising Plan
Jeevan Scientific Technology Limited (JSTL) has approved a capital raising plan of Rs. 30.74 crore through convertible warrants and equity shares. The plan includes issuing 35,00,000 convertible warrants at Rs. 40 per warrant and 41,85,000 equity shares at Rs. 40 per share. The warrants will be allotted to both promoters and non-promoters, while the equity shares are exclusively for non-promoters. The company also plans to increase its authorized share capital from Rs. 21 crore to Rs. 25 crore. An Extraordinary General Meeting is scheduled for November 12, 2025, to seek shareholder approval. Post-allotment, promoters' holding is expected to be 38.37%, with public holding at 61.63%.
 no imag found
1 Year Returns:+52.71%
Industry Peers
Syngene International
415.60
(-0.75%)
Indegene
452.10
(-1.77%)
Suven Life Sciences
130.19
(-2.75%)
Vimta Labs
401.35
(-5.34%)
Take Solutions
38.85
(+2.00%)
Bilcare
51.68
(-2.20%)
Adeshwar Meditex
16.50
(-100.00%)
Vanta Bioscience
14.90
(-10.72%)